The most important thing right now is the CD12 data. The uplisting will occur when all the stars align. I'm not one bit concerned with the SP if we hit our CD12 endpoint(s). The SP will rise whether we are still on the OTC or NASDAQ. Once we get an EUA or approval, the other indications will still draw other investors long after Covid is under control.